آیا استرس اکسیداتیو عامل ایجاد مقاومت به انسولین در زنان مبتلا به تخمدان پلی‌کیستیک است؟

نوع مقاله : مقاله مروری

نویسنده

دانشیار، مرکز تحقیقات بهداشت باروری ولی‌عصر (عج)، بیمارستان ولی‌عصر (عج)، مجتمع بیمارستانی امام خمینی، دانشگاه علوم پزشکی تهران، تهران، ایران

چکیده

مقدمه: سندرم تخمدان پلی‌کیستیک با درجه‌ی شیوع 12-4 درصد، شایع‌ترین اختلال غدد داخلی (اندوکرین)- متابولیکی زنان در سن باروری می‌باشد. اختلال باروری در زنان مبتلا به تخمدان پلی‌کیستیک شامل هایپرانسولینمی، هایپرآندروژنیسم، عدم تخمک‌گذاری مزمن و ناباروری می‌باشد. هدف از انجام این مطالعه‌ی مروری، شناسایی و تأیید نقش مهم استرس اکسیداتیو در ایجاد مقاومت به انسولین در سندرم تخمدان پلی‌کیستیک بود.روش‌ها: برای انجام این مطالعه، تمام اطلاعات مربوط از طریق پایگاه‌های داده مانند PubMed و Google scholar جمع‌آوری شد. این اطلاعات، از بین 100 مقاله بین سال‌های 2020-1989 استخراج شده است. امروزه، ارزیابی وضعیت استرس اکسیداتیو در زنان مبتلا به تخمدان پلی‌کیستیک با استفاده از نشانگرهای گردش خون مانند مالون دی‌آلدئید (MDA)، سوپراکسید دیسموتاز (SOD) و گلوتاتیون پراکسیداز (GPX) انجام می‌شود.یافته‌ها: مقاومت به انسولین می‌تواند با شرایط ایجاد اکسیداتیو استرس در زنان مبتلا به تخمدان پلی‌کیستیک همراه باشد. از این رو، به دست آوردن شاخص استرس اکسیداتیو را می‌توان ارزشمند و معرف بروز اختلات متابولیکی در این سندرم دانست.نتیجه‌گیری: استرس اکسیداتیو، می‌تواند یک نقش کلیدی در روند ایجاد مقاومت به انسولین داشته باشد. از این رو، ارزیابی شاخص استرس اکسیداتیو، می‌تواند به شناسایی علل متابولیکی ناشناخته‌ی سندرم تخمدان پلی‌کسیتیک کمک نماید.

کلیدواژه‌ها

عنوان مقاله [English]

Does Oxidative Stress Cause Insulin Resistance in Women with Polycystic Ovary Syndrome?

نویسنده [English]

  • Farideh Zafari-Zangeneh
Associate Professor, Vali Asr Reproductive Health Research Center, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran
چکیده [English]

Background: Polycystic ovary syndrome (PCOS), with a prevalence of 4-12 percent, is the most common endocrine-metabolic disorder in reproductive age of women. Reproductive disorders in women with PCO include hyperinsulinemia, hyperandrogenism, chronic anovulation, and infertility. The purpose of this paper was to review and confirm the important role of oxidative stress in creating insulin resistance in this syndrome.Methods: All relevant information was collected through databases such as PubMed and Google Scholar, which was extracted from a total of 100 articles between 1989-2020. Today, the assessment of oxidative stress in women with PCO is performed using circulatory markers such as malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione peroxidase (GPX).Findings: Insulin resistance can be associated with the conditions of oxidative stress in women with PCO. Therefore, obtaining oxidative stress index can be considered valuable, and represent the occurrence of metabolic disorders in this syndrome.Conclusion: Oxidative stress can play a key role in insulin resistance. Therefore, the oxidative stress index can help to understand unknown metabolic causes of this syndrome.

کلیدواژه‌ها [English]

  • Oxidative Stress
  • Hyperinsulinemia
  • Insulin Resistance
  • Polycystic ovary syndrome

مراجع

  1. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011; (2): CD007506.
  2. Tehrani FR, Simbar M, Tohidi M, Hosseinpanah F, Azizi F. The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reprod Biol Endocrinol 2011; 9: 39.
  3. Rosenfield RL. Clinical review: Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92(3): 787-96.
  4. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: A systematic review and meta-analysis. Hum Reprod Update 2010; 16(4): 347-63.
  5. Chereau A. Memoires pour Servir à l'Étude des Maladies des Ovaires. Paris, France: Fortin, Masson; 1844. [In French].
  6. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19(1): 41-7.
  7. Jin P, Xie Y. Treatment strategies for women with polycystic ovary syndrome. Gynecol Endocrinol 2018; 34(4): 272-7.
  8. Lanzo E, Monge M, Trent M. Diagnosis and Management of Polycystic Ovary Syndrome in Adolescent Girls. Pediatr Ann 2015; 44(9): e223-e230.
  9. Silva E, Almeida H, Castro JP. (In)Fertility and Oxidative Stress: New Insights into Novel Redox Mechanisms Controlling Fundamental Reproductive Processes. Oxidative Medicine and Cellular Longevity 2020; 2020: 4674896.
  10. Sharlip ID, Jarow JP, Belker AM, Lipshultz LI, Sigman M, Thomas AJ, et al. Best practice policies for male infertility. Fertil Steril 2002; 77(5): 873-82.
  11. Agarwal A, Gupta S, Sekhon L, Shah R. Redox considerations in female reproductive function and assisted reproduction: from molecular mechanisms to health implications. Antioxid Redox Signal 2008; 10(8): 1375-403.
  12. Cadenas E. Biochemistry of oxygen toxicity. Annu Rev Biochem 1989; 58: 79-110.
  13. Huang HY, Helzlsouer KJ, Appel LJ. The effects of vitamin C and vitamin E on oxidative DNA damage: results from a randomized controlled trial. Cancer Epidemiol Biomarkers Prev 2000; 9(7): 647-52.
  14. Riley PA. Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int J Radiat Biol 1994; 65(1): 27-33.
  15. Cadenas E, Davies KJ. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 2000; 29(3-4): 222-30.
  16. Demidchik V. Mechanisms of oxidative stress in plants: From classical chemistry to cell biology. Environmental and Experimental Botany 2015; 109: 212-28.
  17. Siti HN, Kamisah Y, Kamsiah J. The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). Vascul Pharmacol 2015; 71: 40-56.
  18. Tiwari BK, Pandey KB, Abidi AB, Rizvi SI. Markers of Oxidative Stress during Diabetes Mellitus. J Biomark 2013; 2013: 378790.
  19. Salim S. Oxidative stress and psychological disorders. Curr Neuropharmacol 2014; 12(2): 140-7.
  20. Sosa V, Moline T, Somoza R, Paciucci R, Kondoh H, LLeonart ME. Oxidative stress and cancer: an overview. Ageing Res Rev 2013; 12(1): 376-90.
  21. Murri M, Luque-Ramirez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update 2013; 19(3): 268-88.
  22. Zhao Y, Zhao B. Oxidative Stress and the Pathogenesis of Alzheimer's Disease. Oxidative Medicine and Cellular Longevity 2013; 2013: 316523.
  23. Ohl K, Tenbrock K, Kipp M. Oxidative stress in multiple sclerosis: Central and peripheral mode of action. Exp Neurol 2016; 277: 58-67.
  24. Abuelo A, Hernandez J, Benedito JL, Castillo C. Oxidative stress index (OSi) as a new tool to assess redox status in dairy cattle during the transition period. Animal 2013; 7(8): 1374-8.
  25. Geetha A, Lakshmi Priya MD, Jeyachristy SA, Surendran R. Level of oxidative stress in the red blood cells of patients with liver cirrhosis. Indian J Med Res 2007; 126(3): 204-10.
  26. Nasiri N, Moini A, Eftekhari-Yazdi P, Karimian L, Salman-Yazdi R, Zolfaghari Z, et al. Abdominal obesity can induce both systemic and follicular fluid oxidative stress independent from polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2015; 184: 112-6.
  27. Savic-Radojevic A, Bozic A, I, Coric V, Bjekic-Macut J, Radic T, Zarkovic M, et al. Effect of hyperglycemia and hyperinsulinemia on glutathione peroxidase activity in non-obese women with polycystic ovary syndrome. Hormones (Athens) 2015; 14(1): 101-8.
  28. Gonzalez F, Nair KS, Daniels JK, Basal E, Schimke JM. Hyperandrogenism sensitizes mononuclear cells to promote glucose-induced inflammation in lean reproductive-age women. Am J Physiol Endocrinol Metab 2012; 302(3): E297-E306.
  29. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 2007; 121(11): 2381-6.
  30. Zuo T, Zhu M, Xu W. Roles of Oxidative Stress in Polycystic Ovary Syndrome and Cancers. Oxid Med Cell Longev 2016; 2016: 8589318.
  31. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25(2): 544-51.
  32. Ellis KJ. Selected body composition methods can be used in field studies. J Nutr 2001; 131(5): 1589S-95S.
  33. Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 2001; 16(6): 1255-60.
  34. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002; 26(7): 883-96.
  35. Holguin F, Fitzpatrick A. Obesity, asthma, and oxidative stress. J Appl Physiol (1985) 2010; 108(3): 754-9.
  36. Khan NI, Naz L, Yasmeen G. Obesity: an independent risk factor for systemic oxidative stress. Pak J Pharm Sci 2006; 19(1): 62-5.
  37. Kumanyika SK. The obesity epidemic: looking in the mirror. Am J Epidemiol 2007; 166(3): 243-5.
  38. Victor VM, Rovira-Llopis S, Banuls C, Diaz-Morales N, Martinez de MA, Rios-Navarro C, et al. Insulin Resistance in PCOS Patients Enhances Oxidative Stress and Leukocyte Adhesion: Role of Myeloperoxidase. PLoS One 2016; 11(3): e0151960.
  39. Lee SH, Zabolotny JM, Huang H, Lee H, Kim YB. Insulin in the nervous system and the mind: Functions in metabolism, memory, and mood. Mol Metab 2016; 5(8): 589-601.
  40. Air EL, Strowski MZ, Benoit SC, Conarello SL, Salituro GM, Guan XM, et al. Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity. Nat Med 2002; 8(2): 179-83.
  41. Timper K, Bruning JC. Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity. Dis Model Mech 2017; 10(6): 679-89.
  42. Falkowska A, Gutowska I, Goschorska M, Nowacki P, Chlubek D, Baranowska-Bosiacka I. Energy Metabolism of the Brain, Including the Cooperation between Astrocytes and Neurons, Especially in the Context of Glycogen Metabolism. Int J Mol Sci 2015; 16(11): 25959-81.
  43. Zafari ZF, Abdollahi A, Aminee F, Naghizadeh MM. Locus coeruleus lesions and PCOS: role of the central and peripheral sympathetic nervous system in the ovarian function of rat. Iran J Reprod Med 2012; 10(2): 113-20.
  44. Lansdown A, Rees DA. The sympathetic nervous system in polycystic ovary syndrome: a novel therapeutic target? Clin Endocrinol (Oxf) 2012; 77(6): 791-801.
  45. Barria A, Leyton V, Ojeda SR, Lara HE. Ovarian steroidal response to gonadotropins and beta-adrenergic stimulation is enhanced in polycystic ovary syndrome: role of sympathetic innervation. Endocrinology 1993; 133(6): 2696-703.
  46. Codner E, Escobar-Morreale HüF. Hyperandrogenism and Polycystic Ovary Syndrome in Women with Type 1 Diabetes Mellitus. The Journal of Clinical Endocrinology & Metabolism 2007; 92(4): 1209-16.
  47. Chen Y, Fang SY. Potential genetic polymorphisms predicting polycystic ovary syndrome. Endocr Connect 2018; 7(5): R187-R195.
  48. Jafarian T, Naghizadeh MM, Salmani A, Nejad Fathe Moghadam S, Zangeneh FZ. Are beta2-Adrenergic Receptor Gene Single-Nucleotide Polymorphisms Associated with Polycystic Ovary Syndrome? A Pharmacogenetic Study. Gynecol Obstet (Sunnyvale) 2015; 5: 343.
  49. Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289(5487): 2122-5.
  50. Fruzzetti F, Perini D, Lazzarini V, Parrini D, Genazzani AR. Hyperandrogenemia influences the prevalence of the metabolic syndrome abnormalities in adolescents with the polycystic ovary syndrome. Gynecol Endocrinol 2009; 25(5): 335-43.
  51. Bu Z, Dai W, Guo Y, Su Y, Zhai J, Sun Y. Overweight and obesity adversely affect outcomes of assisted reproductive technologies in polycystic ovary syndrome patients. Int J Clin Exp Med 2013; 6(10): 991-5.
  52. Maciejczyk M, Zebrowska E, Chabowski A. Insulin Resistance and Oxidative Stress in the Brain: What's New? Int J Mol Sci 2019; 20(4): 874.
  53. Sripetchwandee J, Chattipakorn N, Chattipakorn SC. Links Between Obesity-Induced Brain Insulin Resistance, Brain Mitochondrial Dysfunction, and Dementia. Front Endocrinol (Lausanne) 2018; 9: 496.
  54. Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 2003; 88(6): 2399-403.
  55. Macut D, Bjekic-Macut J, Savic-Radojevic A. Dyslipidemia and oxidative stress in PCOS. Front Horm Res 2013; 40: 51-63.
  56. Kaya C, Erkan AF, Cengiz SD, Dunder I, Demirel OE, Bilgihan A. Advanced oxidation protein products are increased in women with polycystic ovary syndrome: relationship with traditional and nontraditional cardiovascular risk factors in patients with polycystic ovary syndrome. Fertil Steril 2009; 92(4): 1372-7.
  57. Bairey Merz CN, Elboudwarej O, Mehta P. The autonomic nervous system and cardiovascular health and disease: A complex balancing act. JACC Heart Fail 2015; 3(5): 383-5.
  58. Chen C, Smothers J, Lange A, Nestler JE, Strauss Iii JF, Wickham Iii EP. Sex hormone-binding globulin genetic variation: associations with type 2 diabetes mellitus and polycystic ovary syndrome. Minerva Endocrinol 2010; 35(4): 271-80.
  59. Nitsche K, Ehrmann DA. Obstructive sleep apnea and metabolic dysfunction in polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab 2010; 24(5): 717-30.
  60. Zangeneh F. Polycystic Ovary Syndrome and Sympathoexcitation: Management of Stress and Lifestyle. Journal of Biology and Today's World 2017; 6: 146-54.
  61. Mancia G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens 2007; 25(5): 909-20.
  62. Lim SS, Kakoly NS, Tan JWJ, Fitzgerald G, Bahri KM, Joham AE, et al. Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Obes Rev 2019; 20(2): 339-52.
  63. Mahalingaiah S, Diamanti-Kandarakis E. Targets to treat metabolic syndrome in polycystic ovary syndrome. Expert opinion on therapeutic targets 2015; 19: 1-14.
  64. Zhu S, Zhang B, Jiang X, Li Z, Zhao S, Cui L, et al. Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril 2019; 111(1): 168-77.
  65. Stener-Victorin E, Ploj K, Larsson BM, Holmang A. Rats with steroid-induced polycystic ovaries develop hypertension and increased sympathetic nervous system activity. Reprod Biol Endocrinol 2005; 3: 44.
  66. Heider U, Pedal I, Spanel-Borowski K. Increase in nerve fibers and loss of mast cells in polycystic and postmenopausal ovaries. Fertil Steril 2001; 75(6): 1141-7.
  67. Dissen GA, Garcia-Rudaz C, Paredes A, Mayer C, Mayerhofer A, Ojeda SR. Excessive ovarian production of nerve growth factor facilitates development of cystic ovarian morphology in mice and is a feature of polycystic ovarian syndrome in humans. Endocrinology 2009; 150(6): 2906-14.
  68. Zangeneh F, Bagheri M, Naghizadeh MM. Hyponeurotrophinemia in Serum of Women with Polycystic Ovary Syndrome as a Low Grade Chronic Inflammation. Open Journal of Obstetrics and Gynecology 2015; 05: 459-69.
  69. Blazquez E, Velazquez E, Hurtado-Carneiro V, Ruiz-Albusac JM. Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease. Front Endocrinol (Lausanne) 2014; 5: 161.
  70. Kishi T. Regulation of the sympathetic nervous system by nitric oxide and oxidative stress in the rostral ventrolateral medulla: 2012 Academic Conference Award from the Japanese Society of Hypertension. Hypertens Res 2013; 36(10): 845-51.
  71. Lara HE, Dorfman M, Venegas M, Luza SM, Luna SL, Mayerhofer A, et al. Changes in sympathetic nerve activity of the mammalian ovary during a normal estrous cycle and in polycystic ovary syndrome: Studies on norepinephrine release. Microsc Res Tech 2002; 59(6): 495-502.
  72. Zangeneh FZ, Mohammadi A, Ejtemaeimehr S, Naghizadeh MM, Fatemeh A. The role of opioid system and its interaction with sympathetic nervous system in the processing of polycystic ovary syndrome modeling in rat. Arch Gynecol Obstet 2011; 283(4): 885-92.
  73. Tellechea ML, Muzzio DO, Iglesias Molli AE, Belli SH, Graffigna MN, Levalle OA, et al. Association between beta2-adrenoceptor (ADRB2) haplotypes and insulin resistance in PCOS. Clin Endocrinol (Oxf) 2013; 78(4): 600-6.
  74. Ciccarelli M, Santulli G, Pascale V, Trimarco B, Iaccarino G. Adrenergic receptors and metabolism: role in development of cardiovascular disease. Front Physiol 2013; 4: 265.
  75. Desai V, Prasad NR, Manohar SM, Sachan A, Narasimha SR, Bitla AR. Oxidative stress in non-obese women with polycystic ovarian syndrome. J Clin Diagn Res 2014; 8(7): CC01-CC03.
  76. Kyriakis JM, Avruch J. Sounding the alarm: protein kinase cascades activated by stress and inflammation. J Biol Chem 1996; 271(40): 24313-6.
  77. van Montfort RL, Congreve M, Tisi D, Carr R, Jhoti H. Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B. Nature 2003; 423(6941): 773-7.
  78. Bloch-Damti A, Bashan N. Proposed mechanisms for the induction of insulin resistance by oxidative stress. Antioxid Redox Signal 2005; 7(11-12): 1553-67.
  79. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002; 23(5): 599-622.
  80. Potashnik R, Bloch-Damti A, Bashan N, Rudich A. IRS1 degradation and increased serine phosphorylation cannot predict the degree of metabolic insulin resistance induced by oxidative stress. Diabetologia 2003; 46(5): 639-48.
  81. D'Alessandris C, Lauro R, Presta I, Sesti G. C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser 612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. Diabetologia 2007; 50(4): 840-9.
  82. Copps KD, Hancer NJ, Qiu W, White MF. Serine 302 Phosphorylation of Mouse Insulin Receptor Substrate 1 (IRS1) Is Dispensable for Normal Insulin Signaling and Feedback Regulation by Hepatic S6 Kinase. J Biol Chem 2016; 291(16): 8602-17.
  83. Zhao Y, Zhang C, Huang Y, Yu Y, Li R, Li M, et al. Up-regulated expression of WNT5a increases inflammation and oxidative stress via PI3K/AKT/NF-kappaB signaling in the granulosa cells of PCOS patients. J Clin Endocrinol Metab 2015; 100(1): 201-11.
  84. Gonzalez F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome.
  85. J Clin Endocrinol Metab 2006; 91(1): 336-40.
  86. Victor VM, Rocha M, Banuls C, Alvarez A, de PC, Sanchez-Serrano M, et al. Induction of oxidative stress and human leukocyte/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance. J Clin Endocrinol Metab 2011; 96(10): 3115-22.
  87. Gonzalez F, Rote NS, Minium J, Kirwan JP. In vitro evidence that hyperglycemia stimulates tumor necrosis factor-alpha release in obese women with polycystic ovary syndrome. J Endocrinol 2006; 188(3): 521-9.
  88. Zafari ZF, Naghizadeh MM, Masoumi M. Polycystic ovary syndrome and circulating inflammatory markers. Int J Reprod Biomed (Yazd) 2017; 15(6): 375-82.
  89. Makedos A, Goulis DG, Arvanitidou M, Mintziori G, Papanikolaou A, Makedou A, et al. Increased serum C-reactive protein levels in normal weight women with polycystic ovary syndrome. Hippokratia 2011; 15(4): 323-6.
  90. Orio F, Jr., Palomba S, Cascella T, Di BS, Manguso F, Tauchmanova L, et al. The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90(1): 2-5.
  91. Banuls C, Rovira-Llopis S, Martinez de MA, Veses S, Jover A, Gomez M, et al. Metabolic syndrome enhances endoplasmic reticulum, oxidative stress and leukocyte-endothelium interactions in PCOS. Metabolism 2017; 71: 153-62.
  92. Bannigida DM, Nayak BS, Vijayaraghavan R. Insulin resistance and oxidative marker in women with PCOS. Arch Physiol Biochem 2020; 126(2): 183-6.
  93. Kurdoglu Z, Ozkol H, Tuluce Y, Koyuncu I. Oxidative status and its relation with insulin resistance in young non-obese women with polycystic ovary syndrome. J Endocrinol Invest 2012; 35(3): 317-21.
  94. Sekar N, Garmey JC, Veldhuis JD. Mechanisms underlying the steroidogenic synergy of insulin and luteinizing hormone in porcine granulosa cells: joint amplification of pivotal sterol-regulatory genes encoding the low-density lipoprotein (LDL) receptor, steroidogenic acute regulatory (stAR) protein and cytochrome P450 side-chain cleavage (P450scc) enzyme. Mol Cell Endocrinol 2000; 159(1-2): 25-35.
  95. Rice S, Christoforidis N, Gadd C, Nikolaou D, Seyani L, Donaldson A, et al. Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum Reprod 2005; 20(2): 373-81.
  96. Pisoschi AM, Pop A. The role of antioxidants in the chemistry of oxidative stress: A review. Eur J Med Chem 2015; 97: 55-74.
  97. Mangmool S, Denkaew T, Parichatikanond W, Kurose H. Beta-adrenergic Receptor and Insulin Resistance in the Heart. Biomol Ther (Seoul) 2017; 25(1): 44-56.
  98. Wang F, Wang S, Zhang Z, Lin Q, Liu Y, Xiao Y, et al. Defective insulin signaling and the protective effects of dimethyldiguanide during follicular development in the ovaries of polycystic ovary syndrome. Mol Med Rep 2017; 16(6): 8164-70.
  99. Liu J, Wu DC, Qu LH, Liao HQ, Li MX. The role of mTOR in ovarian Neoplasms, polycystic ovary syndrome, and ovarian aging. Clin Anat 2018; 31(6): 891-8.
  100. Asensio C, Jimenez M, Kuhne F, Rohner-Jeanrenaud F, Muzzin P. The lack of beta-adrenoceptors results in enhanced insulin sensitivity in mice exhibiting increased adiposity and glucose intolerance. Diabetes 2005; 54(12): 3490-5.
مجله دانشکده پزشکی اصفهان
دوره 38، شماره 581 - شماره پیاپی 581
مرداد و شهریور 1399
صفحه 450-462

فایل ها

سابقه مقاله

  • تاریخ دریافت: 27 اردیبهشت 1399
  • تاریخ بازنگری: 11 آبان 1403
  • تاریخ پذیرش: 17 فروردین 1401

هم رسانی

ارجاع به این مقاله

آمار